We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Low Vitamin D Predicts Aggressive Prostate Cancer

By LabMedica International staff writers
Posted on 14 Mar 2016
Print article
Image: Histopathology photomicrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Gleason pattern 4, from prostate currettings (Photo courtesy of Nephron).
Image: Histopathology photomicrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Gleason pattern 4, from prostate currettings (Photo courtesy of Nephron).
Lower serum vitamin D levels have been associated with an increased risk of aggressive prostate cancer and among men with localized prostate cancer, especially with low- or intermediate-risk disease; vitamin D may serve as an important biomarker of disease aggression.

Deficient vitamin D blood levels in men can predict aggressive prostate cancer identified at the time of surgery and this finding is important because it can offer guidance to men and their doctors who may be considering active surveillance, in which they monitor the cancer rather than remove the prostate.

A team of scientists led by those at Northwestern University (Chicago, IL, USA) assess the relationship between adverse pathology at the time of radical prostatectomy and serum 25-hydroxyvitamin D (25-OH D) levels. The team performed a cross-sectional study carried out from 2009 to 2014, nested within a large epidemiologic study of 1,760 healthy controls and men undergoing prostate cancer screening. In total, 190 men underwent radical prostatectomy in the cohort. Adverse pathology was defined as the presence of primary Gleason 4 or any Gleason 5 disease, or extraprostatic extension. The median age in the cohort was 64.0 years.

Of that group, 87 men had aggressive prostate cancer. Those with aggressive cancer had a median level of 22.7 ng/mL of vitamin D, significantly below the normal level of more than 30 ng/mL. The average vitamin D level in Chicago during the winter is about 25 ng/mL. On multivariate analysis, controlling for age, serum prostate specific antigen, and abnormal digital rectal examination, serum 25-OH D less than 30 ng/mL was associated with increased odds of adverse pathology (odds ratio = 2.64). The relationship between vitamin D and prostate cancer may explain some disparities seen in prostate cancer, especially among African American men. Prior studies have shown that African American men who live in low sunlight locations are up to 1.5 times more likely to have vitamin D deficiency than Caucasian men.

Adam B. Murphy, MD, an assistant professor of urology and corresponding author of the study, said, “Vitamin D deficiency may predict aggressive prostate cancer as a biomarker. Men with dark skin, low vitamin D intake or low sun exposure should be tested for vitamin D deficiency when they are diagnosed with an elevated prostate-specific antigen (PSA) or prostate cancer. Then a deficiency should be corrected with supplements.” The study was published on February 22, 2016, in the Journal of Clinical Oncology.

Related Links:

Northwestern University 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: Researchers have found a way to spot the debilitating disease Alzheimer\'s before it develops into dementia (Photo courtesy of 123RF)

Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia

Alzheimer’s disease is well known for its slow development over many years, which typically leads to treatment interventions only after the disease has advanced to stages where it may be nearly impossible... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ASTar System has received US FDA 510(k) clearance (Photo courtesy of Q-linea AB)

Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections

Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. In the United States alone, approximately two million individuals are... Read more

Pathology

view channel
Image: The new method is quick and easy, and can also be used by non-medical personnel. (Photo courtesy of Zoratto et al. Advanced Science 2024, edited)

New Blood Test Device Modeled on Leeches to Help Diagnose Malaria

Many individuals have a fear of needles, making the experience of having blood drawn from their arm particularly distressing. An alternative method involves taking blood from the fingertip or earlobe,... Read more